Research analysts at StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a note issued to investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
The company has a market cap of $45.46 million, a price-to-earnings ratio of -0.07 and a beta of 1.53. Nabriva Therapeutics has a 1 year low of $1.22 and a 1 year high of $8.45. The stock’s 50-day moving average is $0.14. The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12.
Nabriva Therapeutics Company Profile
Featured Stories
- Five stocks we like better than Nabriva Therapeutics
- What to Know About Investing in Penny Stocks
- Joby Aviation Stock: The Case for Upside Just Got Stronger
- What Investors Need to Know About Upcoming IPOs
- Conviction Firms for Microsoft’s Double-Digit Stock Upside
- What is the Australian Securities Exchange (ASX)
- 5 Aggressive Growth Stocks for Long-Term Investors
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.